Scott Rocklage Moving Forward as a Career Life Science Executive at 5AM Ventures

Dr. Scott Rocklage, Ph.D., has been Managing Partner at 5AM Ventures from 2004. He joined the firm in 2003 as a business Partner. He served as CEO at EPIRUS Biopharmaceuticals, temporarily, in mid-2016. He was also the head and President at Amersham Health and Executive Chairman/Co-President at Ilypsa LTD. Scott was also President of Cubist Pharmaceuticals from 1994 to 2001, and it’s CEO from 1994 to 2003.

 

Dr. Rocklage is presently the Board Chairman of Achaogen, Semprus, and Relypsa. He served on the Boards of Pulmatrix, Variation and WaveRx, and the Board of Associates at Whitehead Institute. Scott was formerly Executive Chairman of Miikana (now EntreMed). He has been Director of Pulmatrix from March 2006 and served as Director at MDS Proteomics, Inc. He served as Board Chairman of Semprus Biosciences Corp, and as the Chairman of Cubist Pharmaceuticals Inc.

 

Scott Rocklage earned his B.S. in Chemistry from California University at Berkeley, and a Ph.D. in Chemistry from MIT. He is currently based in Waltham, MA. Scott has well over 20 years experience in healthcare management strategic leadership. His role as a senior executive led to the strong endorsement of three Drug Applications on trial basis by FDA (Teslascan® Omniscan™, and Cubicin®). The federal body further approved six candidates into the clinical drug trials. He also held senior positions at Catalytica and Salutar. Rocklage’s outstanding extensive scientific background has led to the invention of over 30 drug patents for the U.S government. Scott has also featured in not less than 100 peer-reviewed journals.

 

5AM Ventures

 

5AM Ventures is a capital business firm focused on developing future life science businesses to deliver sufficient gains to investors. The company supports organizations that work to solve significant healthcare needs through progressive advances in science and medicine. The Venture’s portfolio company’s front new approaches to identify, avert, and treat a broad assortment of medical conditions.

 

5AM’s asset experts hold strong systematic, medical, legal, operational, and finance capabilities. The broadly harmonized backgrounds present a unique frame to form life science companies. They employ efficiently trained, skilled, and hardworking employees. 5AM is often openly involved in building company strategy, business development, management recruiting, and fundraising. The board members remain committed to contributing ideas and strategies in all key areas of operations.

 

 

 

Leave a Comment